T2 Biosystems has multiple diagnostic applications in development, all designed to enable further breakthroughs in rapid and accurate therapy for patients. The diagnostics are focused on critical, unmet needs in healthcare, where solutions can serve a dual role in improving patient care while reducing costs.
T2Resistance® Panel: T2 Biosystems has partnered with Allergan and CARB-X to develop panels with additional bacterial species and resistance markers. The T2Resistance Panel detects gram-negative and gram-positive resistance markers and is expected to be available for research use only (RUO) in the U.S. and CE marked by the end of 2019.
T2Cauris™ Panel RUO: Direct detection of the emerging superbug Candida auris in patient skin and blood samples and hospital environmental samples are now available for research use only (RUO) assays. The CDC* validated the T2Cauris Panel RUO swab test on patient skin samples and published their 2017 findings in Mycoses.1
1. Sexton DJ, et al. Mycoses, 2018
*The 2017 CDC findings identified the T2Candida auris Panel RUO as a rapid diagnostic that demonstrated significant time advantages (<5 hours) compared to culture methods that take 14 days. Additional data from a collaboration with a European hospital was presented by T2 Biosystems in a poster on the T2Candida auris Panel at IDWeek 2017.